Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies

Anticancer Res. 2016 Aug;36(8):4259-65.

Abstract

Background: It is not clear if progression-free survival (PFS) is a good surrogate end-point for overall survival (OS) for metastatic colorectal cancer if antiangiogenic therapies are used.

Materials and methods: We investigated randomized controlled trials testing antiangiogenic agents against chemotherapy. Log hazard ratios (HR) for PFS and OS were used to construct linear regression models. The surrogate threshold effect (STE) was calculated.

Results: Thirteen studies and 24 comparison arms were available, including 7,179 patients. This model returned a significant correlation between PFS and OS (R(2)=0.68, p<0.001) with an STE of 0.83. Analysis restricted to first-line gave similar results (R(2)=0.68, p<0.001, STE=0.75).

Conclusion: There is a significant correlation between the effect of treatment on PFS and OS. PFS remains a good surrogate end-point for OS even if anti-angiogenic agents are used.

Keywords: Angiogenesis; bevacizumab; colorectal cancer; progression-free survival; surrogate end-points.

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Bevacizumab / administration & dosage*
  • Biomarkers
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / epidemiology
  • Colorectal Neoplasms / pathology
  • Disease-Free Survival
  • Humans
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / epidemiology
  • Neovascularization, Pathologic / pathology
  • Randomized Controlled Trials as Topic

Substances

  • Angiogenesis Inhibitors
  • Biomarkers
  • Bevacizumab